Publication Date:
2015-10-16
Description:
Article Cixutumumab is an anti-IGF-1R monoclonal antibody and is used to treat cancer; however, tumours can develop resistance to the therapy. Here, the authors show that the resistance is mediated by activation of STAT3 that results in an IGF2/IGF-2R signalling loop and recruitment of macrophages. Nature Communications doi: 10.1038/ncomms9499 Authors: Ji-Sun Lee, Ju-Hee Kang, Hye-Jin Boo, Su-Jung Hwang, Sungyoul Hong, Su-Chan Lee, Young-Jun Park, Tae-Moon Chung, Hyewon Youn, Seung Mi Lee, Byoung Jae Kim, June-Key Chung, Yeonseok Chung, William N. William Jr, Young Kee Shin, Hyo-Jong Lee, Seung-Hyun Oh, Ho-Young Lee
Electronic ISSN:
2041-1723
Topics:
Biology
,
Chemistry and Pharmacology
,
Natural Sciences in General
,
Physics
Permalink